A new combination of oral tablet- orphenadrine citrate 50mg, aspirin 770mg and caffeine 60mg was recently approved by the FDA for pain management, as announced a pharmaceutical innovator company on 16 July, 2020. This tablet was designated as the supplemental Abbreviated New Drug Application (sANDA) by FDA on 8 July, 2020 about 2 months before its planned goal date.

It’s approved usage entails- symptomatic relief of pain associated with acute musculoskeletal diseases. Orphenadrine works due to its analgesic properties plus anticholinergic actions for painful conditions. It is best not to be used in patients suffering from glaucoma, achalasia, pyloric or duodenal obstruction, prostatic hypertrophy or bladder neck obstructions keeping in minds its anticholinergic properties. It should not be used in patients with myasthenia gravis or those who are sensitive to caffeine or aspirin. This oral tablet is expected to launch in August 2020.